Announced
Financials
Tags
Single Bidder
Pharmaceuticals
Acquisition
spatial biology
Domestic
Friendly
Pending
Biotechnology
Private
United States
Majority
Venture Capital
Synopsis
Castle Biosciences agreed to acquire Illumina Ventures company, Cernostics, spatial analytics platform, in a cash-and-stock deal worth $30m. The deal also involves future contingent milestone payments in cash or stock of up to $50m. "Acquiring the TissueCypher platform is aligned with our commitment to utilizing innovative technology to provide clinically actionable information that guides disease management and improves patient outcomes. Unfortunately, the incidence of esophageal cancer is increasing at one of the fastest rates of all cancers in the US, so we need new clinical tools to reverse this growth trend in the diagnosis of esophageal adenocarcinoma (EAC)," Derek Maetzold, Castle Biosciences CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.